title: Involvement of hepatic stimulator substance in experimentally induced fibrosis and cirrhosis in the rat.
abstract: Liver fibrosis results from sustained wound healing response to chronic liver injury. Liver cirrhosis, the end stage of the fibrotic process, is characterized by disruption of the entire liver architecture and reduced hepatocyte regenerative ability. Hepatic stimulator substance (HSS) is a liver-specific growth factor triggering hepatocyte proliferation in vitro and in vivo. Previous studies have indicated the involvement of HSS in animal models of acute liver injury. The aim of the present study was to investigate the involvement of HSS in the process of fibrosis and cirrhosis induction. Liver fibrosis and cirrhosis were induced in rats by thioacetamide (TAA) administration (300 mg/l) in the drinking water for 3 months, and animals were killed at 0, 1, 2, and 3 months of treatment. TAA administration resulted in progressively increasing liver fibrosis, leading to the onset of cirrhosis at the end of the experimental time. HSS was continuously produced during the course of fibrosis and cirrhosis induction, peaking at the 2nd month of TAA treatment, coinciding with markers of hepatic proliferative capacity, as thymidine kinase activity and DNA biosynthesis. Significantly reduced HSS activity was noted in cirrhotic liver (3rd month). In this case, the exogenous HSS administration during the 3rd month of TAA treatment suppressed the onset of liver cirrhosis, stimulating the hepatic regenerative capacity. Our data indicate the active participation of HSS in the process of fibrosis and cirrhosis induction post-TAA treatment in rats, suggesting also the beneficial effect of HSS treatment against cirrhosis induction with future possible clinical implications.
authors.affiliation: Department of Forensic Medicine and Toxicology, Medical School, National and Kapodistrian University of Athens, Goudi, 11527 Athens, Greece.
authors.forename: Georgios
authors.initials: G
authors.lastname: Gribilas
authors.forename: Apostolos
authors.initials: A
authors.lastname: Zarros
authors.forename: Athina
authors.initials: A
authors.lastname: Zira
authors.forename: Costas
authors.initials: C
authors.lastname: Giaginis
authors.forename: Gerasimos
authors.initials: G
authors.lastname: Tsourouflis
authors.forename: Charis
authors.initials: C
authors.lastname: Liapi
authors.forename: Chara
authors.initials: C
authors.lastname: Spiliopoulou
authors.forename: Stamatios E
authors.initials: SE
authors.lastname: Theocharis
mesh_terms: D000818:Animals; D036341:Intercellular Signaling Peptides and Proteins; D008103:Liver Cirrhosis / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control; D008115:Liver Regeneration; D008297:Male; D010455:Peptides / Q000008:administration & dosage / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013853:Thioacetamide
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; C073456:hepatic stimulator substance; D013853:Thioacetamide